Video index

1. Call to order

2. Consideration of November 12, 2021, draft meeting minutes

3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 1 of 3)

4. HHS Ethics Policy - refresher training for the board

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 2 of 3)

6. Public comment on single new drugs to be reviewed for the Medicaid PDL (Part 1 of 2)

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 3 of 3)

6. Public comment on single new drugs to be reviewed for the Medicaid PDL (Part 2 of 2)

7. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration

8. Executive work session

9. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration

10. Retrospective drug utilization review (DUR): Conduent, LLC

11. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)

12. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required)

13. Review of action items for next meeting: April 22, 2022, 9:00 a.m

Jan 21, 2022 Drug Utilization Review Board (DURB) Agenda

Full agenda
Share this video

1. Call to order

2. Consideration of November 12, 2021, draft meeting minutes

3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 1 of 3)

4. HHS Ethics Policy - refresher training for the board

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 2 of 3)

6. Public comment on single new drugs to be reviewed for the Medicaid PDL (Part 1 of 2)

5. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) (Part 3 of 3)

6. Public comment on single new drugs to be reviewed for the Medicaid PDL (Part 2 of 2)

7. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration

8. Executive work session

9. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration

10. Retrospective drug utilization review (DUR): Conduent, LLC

11. Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required)

12. Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required)

13. Review of action items for next meeting: April 22, 2022, 9:00 a.m

© 2003-2024 Swagit Productions, LLC